Search

Displaying 1 result
  1. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … The addition of hyaluronidase allows for subcutaneous injection, which is a method often preferable for patients and provides an alternative means of administration for sites lacking IV infrastructure,

    Categories: ocrelizumab, Amino Acids, Peptides, and ProteinsSynonyms: Ocrelizumab, Ocrelizumab (genetical recombination)